Arthneeti
Astrazeneca Pharma India LtdQ1 FY25

Astrazeneca Pharma India Ltd Q1 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹6,764P/E: 97.5Market Cap: ₹16.9K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 2

Margin

Category 4

Fundraise

N/A

Order

Yes

Capex

N/A

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 2
  • AstraZeneca Pharma India is focused on growth through innovation, with multiple new product launches and indication expansions, especially in Oncology, CVRM, and Rare Diseases.
  • Recent launches and collaborations are improving access and are expected to help India become a larger contributor to the global business by 2030.
  • The company reported an 8% quarter-on-quarter growth excluding Lynparza and a 45% year-on-year growth excluding Lynparza for Q1 FY25.
  • India aims to increase its contribution to AstraZeneca's global ambition of USD 80 billion by 2030, with a focus on bringing innovative medicines faster to India.
  • Ongoing pipeline expansion and introduction of novel therapies are expected to transform patient outcomes and drive revenue growth.
  • The company continues assessing sales force and business models to adapt to pipeline needs and maximize benefits.
  • Cost savings from plant closure and business model innovation are expected to positively impact future financials.

See what Astrazeneca Pharma India Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

- No specific mention of any current or future fundraising through debt or equity in the provided AGM transcript. - The company currently operates as a zero-debt entity (Page 17). - There is a focus on managing expenses and growth internally without reference to new capital raising. - The management acknowledges ongoing investments for growth but does not indicate plans for raising new equity or debt. - Dividend payments are ongoing, with an increase mentioned, implying cash flow strength. - Management remains cautious about forward-looking financial commitments and emphasizes prudent asset and financial management. In summary, there is no announced or planned fundraising through debt or equity as per the information on Page 25 and related sections.

See what Astrazeneca Pharma India Ltd management said on order book — free account, 30 seconds.

Capex plans

From the provided transcript on page 24 (August 08, 2024): - The company is focusing on revenue growth and improving access to patients, which may imply ongoing investments in innovative medicines and collaborations. - There was mention of cost savings related to the closure of a plant, indicating strategic operational changes. - Management is actively ensuring the right process for valuable assets like land. - No specific figures or detailed plans for current or future capital expenditure or strategic investment were disclosed. - The company is becoming a specialist organization focusing more on trading products, possibly redirecting investments accordingly. Summary: While no explicit capex or strategic investment figures were provided, AstraZeneca Pharma India is focusing on growth through innovative product launches, collaborations, operational efficiency (including plant closure), and asset management to support future expansion.

Track Astrazeneca Pharma India Ltd — get its next earnings analysis in your feed

Margin guidance

Category 4
  • AstraZeneca Pharma India aims for continued revenue growth, focusing on bringing innovative medicines faster to India and improving access.
  • The company reported strong past performance with 29.3% total revenue growth and 37.6% net sales growth for FY 2023-24.
  • Earnings per share (EPS) stood at Rs. 64.60, reflecting solid profitability.
  • The global parent company has announced an $80 billion revenue ambition by 2030, with India expected to increase its contribution from the current levels.
  • The management foresees India's share in incremental sales potentially reaching 2-3% of the parent’s growth over the next 7-8 years.
  • Focus on oncology, biopharmaceuticals, and rare diseases is expected to drive future growth.
  • The company is committed to managing expenses while ensuring growth and improving stakeholder benefits.
  • No specific forward guidance on exact growth percentages was disclosed, but optimism about future expansion and improved earnings was expressed.

Order book

Yes
The document does not explicitly mention the current or expected order book or pending orders for AstraZeneca Pharma India Limited. However, some relevant points related to business and growth expectations include: - The company is focusing on revenue growth and improving patient access. - Recent launches and collaborations are expected to enhance market presence, especially in oncology and rare diseases. - The company is evaluating new business models to reach diverse markets. - Management is cautious about making forward-looking statements but expects growth in India’s contribution to AstraZeneca’s global targets by 2030. - Cost savings from plant closure and ongoing pipeline assessment could impact future operations positively. - Deferred revenue pertains to the Mankind Pharma arrangement from this year onward. No specific figures or details on order book/pending orders are provided in the transcript.

How does Astrazeneca Pharma India Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature
ThisAstrazeneca Pharma India Ltd
Rev 2Mar 4
See where Astrazeneca Pharma India Ltd sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

How does Astrazeneca Pharma India Ltd rank in Pharmaceuticals & Biotechnology?

Compare Astrazeneca Pharma India Ltd against every Pharmaceuticals & Biotechnology company (Q1 FY25) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

Continue your research

What Astrazeneca Pharma India Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • IOL Chemicals (Q1 FY27)

    Expansion plans supported by capex of INR 200-250 crores annually, with 60% towards expansion/new products and 40% towards efficiency improvements. Key concall…

  • Innova Captab (Q1 FY27)

    The company is confident of achieving 20%+ volume growth backed by steady ramp-up in Jammu and existing facilities. Key concall takeaways from Innova Captab…

  • Glenmark Pharma. (Q1 FY27)

    Chronic respiratory segment in India showing over 25% growth; oncology and cardiovascular segments also strong. Key concall takeaways from Glenmark…

  • Strides Pharma (Q1 FY27)

    markets continue to be broad-based growth drivers, with 17% YoY growth and expansion in B2B and B2C markets including Europe, UK, Nordics, Africa, LATAM, MENA…

Compare:vs Sun Pharmaceutical Industries Ltdvs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →